Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats

PURPOSE: Avitinib is the first third-generation epithelial growth factor receptor (EGFR) inhibitor independently developed in China and is mainly used for treating non-small cell lung cancer. However, pharmacokinetic details are limited. This study explored the in vivo and in vitro effects of avitin...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yong, Meng, Deru, Wang, Shuanghu, Geng, Peiwu, Xu, Tao, Zhou, Quan, Zhou, Yunfang, Li, Wanshu, Chen, Xugao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387736/
https://www.ncbi.nlm.nih.gov/pubmed/34456561
http://dx.doi.org/10.2147/DDDT.S323186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387736/
https://www.ncbi.nlm.nih.gov/pubmed/34456561
http://dx.doi.org/10.2147/DDDT.S323186

Ejemplares similares